X0609 4 2026-06-08 0001759425 Mirum Pharmaceuticals, Inc. MIRM 0001197350 BJERKHOLT ERIC false C/O MIRUM PHARMACEUTICALS, INC. 989 E HILLSDALE BLVD., SUITE 300 FOSTER CITY CA 94404 false true false false CHIEF FINANCIAL OFFICER 1 Common Stock 2026-06-08 4 S 0 2258 92.84 D 47530 D Common Stock 2026-06-08 4 S 0 1175 93.95 D 46355 D Common Stock 2026-06-08 4 S 0 1567 95.12 D 44788 D Common Stock 2026-06-09 4 M 0 2393 26.49 A 47181 D Employee Stock Option (right to buy) 26.49 2026-06-09 4 M 0 2393 0 D 2034-01-22 Common Stock 2393 26653 D Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. . The weighted average sale price for the transaction reported was $92.84, and the range of prices were between $92.485 and $93.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $93.95, and the range of prices were between $93.49 and $94.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. . The weighted average sale price for the transaction reported was $95.12, and the range of prices were between $94.62 and $95.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. 1/4th of the shares vested one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. /s/ Judit Ryvkin, Attorney-in-Fact 2026-06-09